## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average I	burden						
hours per response	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Instruction	1(b).				Inve	estn	nent Co	ompa	any Ac	t of 19	40							
(Print or Type Re	esponses)																	
1. Name and Address of Reporting Person * Fleming Ibelis				2. Issuer Name and Ticker or Trading Symbol HERBALIFE LTD. [HLF]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) 800 W. OLYMPIC BLVD., SUITE 406				3. Date of Earliest Transaction (Month/Day/Year) 02/23/2017							ear)		X Officer (give title below) Other (specify below)  SVP/Managing Dir North America					
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)								_X_ Form	6. Individual or Joint/Group FilingCheck Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person					
LOS ANGELES, CA 90015 (City) (State) (Zip)			Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
				<u> </u>								•	. 1					
(Instr. 3)		2. Transaction Date (Month/Day/Year	2A. Deemed Execution Day any (Month/Day/		n Da	(Instr. 8		(A) or Disposed of (D)						Form:	7. Nature of Indirect Beneficial Ownership			
				(Month/Da		ау	i cai)	Code		Amor	(A) or unt (D) P	rice (msu. 3					(Instr. 4)	
							<u> </u>		e V							Instr. 4)		
Reminder: Repor	rt on a separa	ate line for each cla	ss of securities ber	nefi	cially ov	vned	directly	or in			ho respond to	o the collec	tion of ir	nformation	contained	in SEC	1474 (9-02)	
									this	form a	re not require alid OMB cor	ed to respo	nd unles			III SEC	1474 (9-02)	
			Table II								of, or Benefici							
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, any (Month/Day/Yea	Code		of Derivative		Expira (Mont	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported		Ownership (Instr. 4)		
					Code	V	(A)	(D)	Date Exerci	sable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)	(I) (Instr. 4)		
Stock Appreciation Rights	\$ 59.98	02/23/2017			A		11,547	7	04/30	)/2017	04/30/2024	Common Stock	11,547	\$ 0	19,245 (1	D D		
Stock Appreciation Rights	\$ 30.44	02/23/2017			A		6,525		03/02	2/2017	03/02/2025	Common Stock	6,525	\$ 0	13,050 (2	D D		
Stock Appreciation Rights	\$ 47.8	02/23/2017			A		2,500		05/07	7/2017	05/07/2025	Common Stock	2,500	\$ 0	5,000 (3)	D		
Stock Appreciation Rights	\$ 62.51	02/23/2017			A		2,688		05/09	9/2017	05/09/2026	Common Stock	2,688	\$ 0	2,688 (4)	D		
Reportin	g Own	iers				1	Relation	shins				1						

Other

# Signatures

Fleming Ibelis

/s/ Mark J. Friedman, Attorney-in-Fact for Ibelis Fleming	02/27/2017
**Signature of Reporting Person	Date

10%

Owner

Officer

SVP/Managing Dir North America

Director

### **Explanation of Responses:**

Reporting Owner Name / Address

800 W. OLYMPIC BLVD., SUITE 406

LOS ANGELES, CA 90015

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- On April 30, 2014, the reporting person was granted an award of 19,245 stock appreciation rights ("SARs"). The amount and timing of the vesting of these SARs is dependent upon the (1) achievement by Herbalife Ltd. (the "Company") of certain performance criteria for each of fiscal 2014, 2015 and 2016. The performance criteria for 2016 was met, resulting in 11,547 SARs which will vest on April 30, 2017.
- (2) On March 2, 2015, the reporting person was granted an award of 32,626 SARs. The amount and timing of the vesting of these SARs is dependent upon the achievement by the Company of certain performance criteria for each of fiscal 2015, 2016 and 2017. The performance criteria for 2016 was met, resulting in 6,525 SARs which will vest on March 2, 2017.
- (3) On May 7, 2015, the reporting person was granted an award of 12,500 SARs. The amount and timing of the vesting of these SARs is dependent upon the achievement by the Company of certain performance criteria for each of fiscal 2015, 2016 and 2017. The performance criteria for 2016 was met, resulting in 2,500 SARs which will vest on May 7, 2017.
- (4) On May 9, 2016, the reporting person was granted an award of 13,436 SARs. The amount and timing of the vesting of these SARs is dependent upon the achievement by the Company of certain performance criteria for each of fiscal 2016, 2017 and 2018. The performance criteria for 2016 was met, resulting in 2,688 SARs which will vest on May 9, 2017.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.